Suppr超能文献

E3 泛素连接酶 HRD1 通过促进 Sirtuin 2 的泛素化和降解促进肺肿瘤发生。

E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation.

机构信息

School of Life Sciences, Chongqing University, Chongqing, People's Republic of China.

Department of Pulmonology, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China.

出版信息

Mol Cell Biol. 2020 Mar 16;40(7). doi: 10.1128/MCB.00257-19.

Abstract

The NAD-dependent histone deacetylase sirtuin 2 (SIRT2) plays critical roles in mitosis and cell cycle progression and recently was shown to suppress tumor growth and to be downregulated in several types of cancers. However, the underlying mechanism of SIRT2 downregulation remains unknown. In this study, using bioinformatics, gene expression profiling, protein overexpression approaches, and cell migration assays, we showed that E3 ubiquitin ligase 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase degradation 1 (HRD1) interacts with SIRT2 and promotes its ubiquitination and degradation. Furthermore, we found that HRD1 deficiency induces SIRT2 upregulation and inhibits the growth and tumor formation of lung cancer cells both and Of note, we observed that SIRT2 expression is downregulated in human lung cancer and also negatively correlates with HRD1 expression in these cancers. Additionally, we found that patients with lung adenocarcinoma having lower HRD1 or higher SIRT2 expression levels tend to survive longer. On the basis of these results, we propose a mechanism of lung tumorigenesis that involves HRD1-mediated downregulation of SIRT2 and suggest that interventions targeting HRD1 activity could be a potential therapeutic strategy to treat patients with lung cancer.

摘要

NAD 依赖的组蛋白去乙酰化酶 Sirtuin 2(SIRT2)在有丝分裂和细胞周期进程中发挥关键作用,最近的研究表明它可以抑制肿瘤生长,并在几种类型的癌症中下调。然而,SIRT2 下调的潜在机制尚不清楚。在这项研究中,我们使用生物信息学、基因表达谱分析、蛋白质过表达方法和细胞迁移实验表明,E3 泛素连接酶 3-羟基-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶降解 1(HRD1)与 SIRT2 相互作用,并促进其泛素化和降解。此外,我们发现 HRD1 缺乏会诱导 SIRT2 上调,并抑制肺癌细胞的生长和肿瘤形成。值得注意的是,我们观察到 SIRT2 的表达在人类肺癌中下调,并且在这些癌症中与 HRD1 的表达呈负相关。此外,我们发现具有较低 HRD1 或较高 SIRT2 表达水平的肺腺癌患者的存活时间更长。基于这些结果,我们提出了一种涉及 HRD1 介导的 SIRT2 下调的肺癌发生机制,并表明靶向 HRD1 活性的干预可能是治疗肺癌患者的潜在治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26a7/7076256/edfbc105ad5d/MCB.00257-19-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验